Lecrolyn Sine

Sodium cromoglicate, the active ingredient in Lecrolyn Sine, is a mast cell stabilizer presented as eye drops for ocular use. It treats allergic conjunctivitis, ocular itching and redness caused by allergic eye disease, helping to reduce inflammation and discomfort in the eyes, and is approved for prescription use in the European Union.

GNH USA supplies Lecrolyn Sine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Lecrolyn Sine, a mast cell stabilizer, acts on allergic eye disease pathways to alleviate symptoms. - Allergic conjunctivitis: Reduces ocular inflammation and itching associated with allergic reactions. - Ocular itching: Provides relief from itchiness caused by allergic eye disease. - Redness due to allergic eye disease: Decreases hyperemia and discomfort in the affected eye.

Sodium cromoglicate eye drops may cause ocular or systemic reactions, although most patients tolerate the medication well.

Common Side Effects: - Transient burning or stinging sensation upon instillation - Mild eye redness - Temporary blurred vision - Tear film instability

Serious or Rare Side Effects: - Allergic contact dermatitis of the eyelid - Severe ocular inflammation - Vision loss - Systemic hypersensitivity reaction

When prescribing Lecrolyn Sine, consider the following safety measures. - Pregnancy: Safety not established; use only if clearly needed. - Breastfeeding: Unknown; consider risk vs benefit. - Contact lenses: Remove before administration and wait before reinserting. - Concurrent ocular infection: Evaluate before use. - Allergy to cromoglicate: Contraindicated. - Store at room temperature: keep in original container, protect from light and moisture.

Sodium cromoglicate has a low potential for drug‑drug interactions, but monitor the following.

Major Interactions (Avoid): - Concurrent use with ocular prostaglandin analogs may diminish anti‑inflammatory effect. - Combination with preservative‑rich eye drops may increase ocular irritation.

Moderate Interactions (Monitor Closely): - Use with other mast cell stabilizers may not provide additional benefit. - Co‑administration with topical antihistamines may alter symptom control. - Systemic antihistamines may affect overall allergic response, requiring clinical observation.